Seastar Medical Holding Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seastar Medical Holding Corp. (ICU) on January 9, 2023, covering an event that occurred on January 6, 2023. The Company is an emerging growth company incorporated in Delaware, focused on developing the Selective Cytopheretic Device (SCD).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material event reported is the submission of an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA). This submission requests approval to initiate a pivotal study evaluating the SCD's effectiveness in reducing hyperinflammation in adults with acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT).
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the IDE submission. The filing does not provide specific financial guidance, updated outlooks, or detailed risk factors beyond the inherent uncertainties of FDA regulatory approval processes. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the status of the FDA IDE application and the timeline for approval.
- Confirm the design and enrollment criteria of the proposed pivotal study for the SCD.
- Review the press release filed as Exhibit 99.1 for additional details on the clinical trial scope.
- Monitor subsequent filings for updates on regulatory decisions or changes to the study protocol.